About Us


About Us

Changes to global attitudes in the last decade has seen legalization, followed by huge market growth, of medicines employing previously prohibited substances - cannabis being the leading example.


Pharmadelic Labs is a biotech company focusing on improving and patenting engineering processes for the biosynthesis of compounds - primarily psilocybin, the psychoactive component of magic mushrooms.

Now, leading scientists, academic institutions and government administrations are turning their attention to the benefits of psilocybin as a potential treatment for the global problems of mental health and end of life care. The ability to produce this molecule quickly, economically and cleanly, as Pharmadelic Labs is aiming to achieve, will be in high demand when psilocybin gains widespread acceptance.


Psilocybin is a psychoactive substance found in around 200 species of mushroom. Much of the science remains surrounding the molecule remains unexplored, but it has been theorized that psilocybin works with the body's serotonin system to heighten emotional responses, which helps to actively confront mental health issues such as depression.

More and more studies are examining the properties of this molecule, and the seismic effects that it can have on the huge global problem of treating mental health.

Did you know?
Psilocybin was designated Schedule I in the 1970 Criminal Substances Act, making it a drug with "no currently accepted medical use and a high potential for abuse". However, this was largely a politically motivated decision made to oppose 1960s counterculture.